AI in drug discovery

R&D

Artificial Intelligence (AI) is at the heart of the latest global transformation, not least within the biopharmaceutical industry.

R&D

Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.

R&D

The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.

News

AI-powered techbio firm Caris Life Sciences has raised the target price for its IPO, pointing to strong demand among investors.

News

AstraZeneca taps China's CSPC Pharma for new drug candidates a second time – and the latest AI-focused alliance is a big one.

News

Novo Nordisk and tech giant NVIDIA have joined forces on a new project that aims to speed up drug discovery using generative AI.